Remove 2008 Remove Biosimilars Remove Chemotherapy
article thumbnail

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacy Times

Eligible patients include adults (≥ 18 years) diagnosed with CML receiving imatinib as first-line therapy for more than 1 month between 2008 and 2023. Materials and Methods This retrospective observational study utilized the Carolina Data Warehouse for Health electronic health record (EHR) database.

Dosage 26
article thumbnail

Beating the Big C

Pharmaceutical Technology

The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. “Companies used to be universally protected by patents but there is a pathway to approval opening up for biosimilar legislation. .

article thumbnail

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

PharmaShots

Some companies accept the offered period and open doors to biological drugs or biosimilars. Company: Sanofi Generic Name: Plerixafor First Approval Date: Dec 15, 2008 Patent Expiration: Jul 2023 2022 Sales: $281.5M It is the only drug in its class of chemotherapy and is developed from the natural substance found in a sea sponge.